Jeremy Veenstra-VanderWeele uses molecular and translational neuroscience research tools in the pursuit of new treatments for autism.
Jeremy Veenstra-VanderWeele
From this contributor
Why serotonin medications may yet help children with autism
A class of medications used to treat obsessive-compulsive disorder seems to ease compulsive behaviors in adults with autism. Why can't we tell if these medications work similarly in children with the condition?
Why serotonin medications may yet help children with autism
By
Jeremy Veenstra-VanderWeele
28 January 2020 | 5 min read
How to evaluate new medications for autism
There are no available medications for treating autism’s core symptoms, but there are several candidates in clinical trials. Jeremy Veenstra-VanderWeele describes the factors researchers must take into account when developing drugs for the disorder.
How to evaluate new medications for autism
By
Jeremy Veenstra-VanderWeele
10 June 2014 | 8 min read
Explore more from The Transmitter
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
Additional data suggest changes in diagnostics underlie increases in autism diagnoses, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 14 September.
By
Jill Adams
15 September 2026 | 2 min read
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
Building brain-computer interfaces at a neurotech company
At Blackrock Neurotech, Spencer Kellis develops implantable devices that help people with brain and spinal cord conditions communicate, move and more.
By
Katie Moisse
15 September 2026 | 8 min read
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.
‘High risk, high reward’: How early-career neuroscientists view their future
The Transmitter and Neuromatch surveyed more than 300 early-career neuroscientists to better understand their unique challenges, career aspirations and support needs.
By
Paige Miranda
15 September 2026 | 0 min watch